Kite Launches CAR T-cell Therapy Operations in Brazil, Singapore and Saudi Arabia
Kite Announces U.S. FDA Clearance of Investigational New Drug Application for Kite-363, a Dual-Targeting CAR T-Cell Therapy Candidate for Large B-Cell Lymphoma
Kite’s Yescarta® (Axicabtagene Ciloleucel) Car T-Cell Therapy Now Widely Available and Publicly Funded for Patients in Australia with Four Types of Aggressive Non-Hodgkin Lymphoma
Kite Announces U.S. FDA Clearance of Investigational New Drug Application for KITE-222, an Anti-CLL-1 CAR T-Cell Therapy Candidate for Acute Myeloid Leukemia
